Investigating a new imaging agent for prostate cancer surgery
Official title: Toxicology (IND-enabling) studies for a novel nerve imaging agent for prostate cancer
Funded at Manzanita Pharmaceuticals, INC. · NIH-11006190 · Data updated 2026-11-12
This study is testing a new tool called NerveLight that helps surgeons see nerves more clearly during prostate cancer surgery, which could make the surgery safer and more effective for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Manzanita Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Woodside, United States) |
| Project start | September 6, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $905,526 |
| NIH project number | 1R44CA295214-01 |
| Project ID | NIH-11006190 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adult males undergoing radical prostatectomy for prostate cancer.
✕Less likely to help
Patients who are not undergoing prostate surgery or those with contraindications to nerve imaging agents may not benefit from this research.
What this research studies
This research focuses on developing NerveLight, a novel nerve imaging agent designed to enhance the safety and effectiveness of radical prostatectomies. The agent is applied topically during surgery to help visualize nerve structures, which can reduce the risk of nerve damage. The study will assess the safety and effectiveness of NerveLight through preclinical trials in animal models, specifically rats and dogs, to ensure it meets FDA guidelines for further clinical use. By using a unique Near InfraRed dye linked to nerve growth factor, the research aims to improve surgical outcomes for prostate cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to safer prostate cancer surgeries with reduced nerve damage and improved recovery for patients.
How similar studies have gone: Preliminary studies in animal models have shown promising results, indicating that similar approaches may be effective, although this specific application is novel.
Where this research is happening
-
Manzanita Pharmaceuticals, INC.
Woodside, United States Active
Researchers
- Principal investigator: Kahl, Stephen B — Manzanita Pharmaceuticals, INC.
- Study coordinator: Kahl, Stephen B
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.